Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613073 | 0.86 | RAB9A (0.53) | RAB9ALMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL3603582 | 0.84 | GRM1 (0.59) | RAB9ALMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL3610908 | 0.83 | GRM1 (0.61) | RAB9ALMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL13316474 | 0.80 | RAB9A (0.47) | RAB9ALMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL3615459 | 0.77 | RAB9A (0.53) | RAB9ALMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL13316476 | 0.77 | RAB9A (0.53) | RAB9ALMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL8162771 | 0.75 | RAB9A (0.48) | RAB9ALMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL8155383 | 0.74 | RAB9A (0.48) | RAB9ALMNAHPGDSMN1; SMN2KDM4E | |
| SCHEMBL3612233 | 0.74 | TP53 (0.55) | LMNAHPGDSMN1; SMN2KDM4EGRM1 | |
| SCHEMBL3608846 | 0.73 | TP53 (0.56) | RAB9ALMNAHPGDSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GLATTHAR RALF | 2010-06-03 | — | — | US | disclosed |
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GLATTHAR RALF | 2010-06-03 | — | — | US | disclosed |
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GLATTHAR RALF | 2010-06-03 | — | — | US | disclosed |
| EP-2132210-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | Novartis AG (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008107418-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107418-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137340-A1 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS | GRM1, GRM2, GRM3 | RAB9A 1068/4885LMNA 4440/4885HPGD 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.